Novel drugs in the management of difficult-to-treat hepatitis C genotypes

Emily J Cartwright, Lesley MillerDepartment of Medicine, Emory University School of Medicine, Atlanta, GA, USABackground: Hepatitis C virus (HCV) infection is the most common chronic bloodborne infection in the United States, with approximately 3.2 million Americans being chronically infected. Rates...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Cartwright EJ, Miller L
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2013
Materias:	Diseases of the digestive system. Gastroenterology RC799-869
Acceso en línea:	https://doaj.org/article/8718e45ca68e48eea21d3274048d5dbc
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:8718e45ca68e48eea21d3274048d5dbc
record_format	dspace
spelling	oai:doaj.org-article:8718e45ca68e48eea21d3274048d5dbc2021-12-02T04:47:10ZNovel drugs in the management of difficult-to-treat hepatitis C genotypes1179-1535https://doaj.org/article/8718e45ca68e48eea21d3274048d5dbc2013-08-01T00:00:00Zhttp://www.dovepress.com/novel-drugs-in-the-management-of-difficult-to-treat-hepatitis-c-genoty-a14110https://doaj.org/toc/1179-1535Emily J Cartwright, Lesley MillerDepartment of Medicine, Emory University School of Medicine, Atlanta, GA, USABackground: Hepatitis C virus (HCV) infection is the most common chronic bloodborne infection in the United States, with approximately 3.2 million Americans being chronically infected. Rates of HCV-related end-stage liver disease and its associated morbidity and mortality have yet to peak, so there is a pressing need for more effective and tolerable HCV treatment. HCV genotypes 1, 4, 5, and 6 are considered difficult to treat, and the need for improved therapies is especially great for persons infected with these genotypes.Current strategies for HCV treatment: Current therapy for genotype 1 HCV infection includes triple therapy with pegylated interferon, ribavirin, and a NS3/4A protease inhibitor. Sustained virologic response (SVR) rates with triple therapy range from 42% to 75%, a vast improvement over pegylated interferon and ribavirin therapy alone. However, response rates remain suboptimal, and triple therapy is associated with significant adverse effects and is only indicated for genotype 1 HCV infection.Novel drugs for HCV treatment: HCV drug development is proceeding at a rapid pace to meet this need. Novel direct acting antiviral agents in several classes, including new NS3/4A serine protease inhibitors, NS5A replication complex inhibitors, NS5B polymerase inhibitors, interferon lambda, and microRNAs, are in varying stages of development. These new therapeutic agents promise SVR rates of up to 100% with durations as short as 12 weeks and, often, fewer adverse effects.Conclusion: New drug development in HCV is proceeding at an unprecedented pace. Novel agents promise higher SVR rates, shorter duration of therapy, and fewer adverse effects than have been possible with HCV therapy to date.Keywords: hepatitis C, direct acting antivirals, genotypeCartwright EJMiller LDove Medical PressarticleDiseases of the digestive system. GastroenterologyRC799-869ENHepatic Medicine: Evidence and Research, Vol 2013, Iss default, Pp 53-61 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	Diseases of the digestive system. Gastroenterology RC799-869
spellingShingle	Diseases of the digestive system. Gastroenterology RC799-869 Cartwright EJ Miller L Novel drugs in the management of difficult-to-treat hepatitis C genotypes
description	Emily J Cartwright, Lesley MillerDepartment of Medicine, Emory University School of Medicine, Atlanta, GA, USABackground: Hepatitis C virus (HCV) infection is the most common chronic bloodborne infection in the United States, with approximately 3.2 million Americans being chronically infected. Rates of HCV-related end-stage liver disease and its associated morbidity and mortality have yet to peak, so there is a pressing need for more effective and tolerable HCV treatment. HCV genotypes 1, 4, 5, and 6 are considered difficult to treat, and the need for improved therapies is especially great for persons infected with these genotypes.Current strategies for HCV treatment: Current therapy for genotype 1 HCV infection includes triple therapy with pegylated interferon, ribavirin, and a NS3/4A protease inhibitor. Sustained virologic response (SVR) rates with triple therapy range from 42% to 75%, a vast improvement over pegylated interferon and ribavirin therapy alone. However, response rates remain suboptimal, and triple therapy is associated with significant adverse effects and is only indicated for genotype 1 HCV infection.Novel drugs for HCV treatment: HCV drug development is proceeding at a rapid pace to meet this need. Novel direct acting antiviral agents in several classes, including new NS3/4A serine protease inhibitors, NS5A replication complex inhibitors, NS5B polymerase inhibitors, interferon lambda, and microRNAs, are in varying stages of development. These new therapeutic agents promise SVR rates of up to 100% with durations as short as 12 weeks and, often, fewer adverse effects.Conclusion: New drug development in HCV is proceeding at an unprecedented pace. Novel agents promise higher SVR rates, shorter duration of therapy, and fewer adverse effects than have been possible with HCV therapy to date.Keywords: hepatitis C, direct acting antivirals, genotype
format	article
author	Cartwright EJ Miller L
author_facet	Cartwright EJ Miller L
author_sort	Cartwright EJ
title	Novel drugs in the management of difficult-to-treat hepatitis C genotypes
title_short	Novel drugs in the management of difficult-to-treat hepatitis C genotypes
title_full	Novel drugs in the management of difficult-to-treat hepatitis C genotypes
title_fullStr	Novel drugs in the management of difficult-to-treat hepatitis C genotypes
title_full_unstemmed	Novel drugs in the management of difficult-to-treat hepatitis C genotypes
title_sort	novel drugs in the management of difficult-to-treat hepatitis c genotypes
publisher	Dove Medical Press
publishDate	2013
url	https://doaj.org/article/8718e45ca68e48eea21d3274048d5dbc
work_keys_str_mv	AT cartwrightej noveldrugsinthemanagementofdifficulttotreathepatitiscgenotypes AT millerl noveldrugsinthemanagementofdifficulttotreathepatitiscgenotypes
_version_	1718401018876657664

Novel drugs in the management of difficult-to-treat hepatitis C genotypes

Ejemplares similares